Network origin in Amrit Nagpal first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Evox Therapeutics Ltd.
 Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom.
7
| Holding Company | Biotechnology | 7 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Amrit Nagpal via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| HUTCHMED (CHINA) LIMITED | Pharmaceuticals: Major | Director/Board Member | |
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
| OXFORD NANOPORE TECHNOLOGIES PLC | Electronic Equipment/Instruments | Director/Board Member | |
| MALLINCKRODT PLC | Pharmaceuticals: Major | Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
University of Melbourne
 University of Melbourne Other Consumer ServicesConsumer Services The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs. | College/University | Doctorate Degree | |
Duke Clinical Research Institute
 Duke Clinical Research Institute Pharmaceuticals: OtherHealth Technology Duke Clinical Research Institute manufactures medical and botanical products. It offers specialized patient databases and clinical and operational expertise. The firm accelerates the development of therapies, diagnostics, and medical devices to humans. The company was founded in 1969 and is headquartered in Durham, NC. | Pharmaceuticals: Other | Corporate Officer/Principal | |
| Imperial College London | College/University | Graduate Degree | |
| University of Aberdeen | College/University | Undergraduate Degree | |
University of Southern California
 University of Southern California Other Consumer ServicesConsumer Services University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA. | College/University | Corporate Officer/Principal | |
| University of Salford | College/University | Undergraduate Degree | |
| Karolinska Institutet | College/University | Doctorate Degree | |
| Royal Institute of Technology | College/University | Graduate Degree | |
JDRF International
 JDRF International Miscellaneous Commercial ServicesCommercial Services JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Director/Board Member | |
| Duke University Medical Center | College/University | Corporate Officer/Principal | |
| ALDER BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Lone Pine Capital (UK) Ltd.
 Lone Pine Capital (UK) Ltd. Investment ManagersFinance Lone Pine Capital UK Ltd. (Lone Pine-UK) is the Great Britain-based alternative investment subsidiary of Lone Pine Capital LLC in the US. Headquartered in London, Lone Pine-UK was founded in 2002 and provides investment management services to pooled investment vehicles as well as pension and profit-sharing plans. | Investment Managers | Chief Executive Officer | |
| Scripps Clinic & Research Foundation | Corporate Officer/Principal | ||
| Thomson Reuters Holdings AB | Corporate Officer/Principal | ||
| The Royal Australasian College of Physicians | Corporate Officer/Principal | ||
| REDX PHARMA PLC | Pharmaceuticals: Major | Director/Board Member | |
| University of West London | College/University | Undergraduate Degree | |
| ASSEMBLY BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member | |
| COMBIGENE AB | Pharmaceuticals: Major | Director/Board Member | |
| Stockholm Business School | College/University | Masters Business Admin | |
Hy. Duke & Son Ltd.
 Hy. Duke & Son Ltd. Specialty StoresRetail Trade Hy. The private company is based in Dorchester, UK, and their fine art salerooms are centrally located in the county town, close to the main Dorchester South railway station. Duke & Son Ltd. is a British company that deals with militaria and sporting goods, as well as silver and objects of vertu. The company also provides valuations for inheritance tax assessment. The company was founded in 1999, and Lee Young has been the CEO of the company since 2017. | Specialty Stores | Corporate Officer/Principal | |
| Leweston School | Director/Board Member | ||
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Concentric Analgesics, Inc.
 Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | Packaged Software | Director/Board Member | |
Vaccitech (UK) Ltd.
 Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
| ORCHARD THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
| IMMATICS N.V. | Biotechnology | Director/Board Member | |
| IsletOne Therapeutics | Founder | ||
| FREELINE THERAPEUTICS HOLDINGS PLC | Biotechnology | Director/Board Member | |
| New Context Ltd. | Director/Board Member | ||
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
| AWAKN LIFE SCIENCES CORP. | Medical/Nursing Services | Director/Board Member | |
Tune Therapeutics, Inc.
 Tune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane. | Pharmaceuticals: Major | Director/Board Member | |
| Larkham Ltd. | Director/Board Member | ||
| Sgw Research Ltd. | Director/Board Member | ||
| The Bridport Literary Festival Ltd. | Director/Board Member | ||
Velia, Inc.
 Velia, Inc. Packaged SoftwareTechnology Services Velia, Inc. is a company based in San Francisco, CA that is focused on harnessing the therapeutic potential of a novel class of human peptides. These peptides regulate biological functions that are vital to human health. The company was founded by Alan Saghatelian, Jonathan Weissman, Eric Olson, and Richard Scheller. John G. McHutchison has been the CEO of the company since 2023. | Packaged Software | Chief Executive Officer | |
Actio Biosciences, Inc.
 Actio Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Actio Biosciences, Inc. is an American precision medicine company that focuses on developing new therapeutics for rare and common diseases by targeting shared genetics. Actio Biosciences was founded in October 2021 and is based in an undisclosed location. The company applies its expertise in genetics, drug discovery, and data sciences to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward potent and precisely targeted therapeutics. The company is led by leaders in genetics and drug development and backed by top healthcare investors. | Pharmaceuticals: Major | Founder | |
| METACRINE, INC. | Biotechnology | Director/Board Member |
Statistics
International
| United Kingdom | 20 |
| United States | 14 |
| Sweden | 7 |
| Australia | 3 |
| Switzerland | 3 |
Sectoral
| Health Technology | 20 |
| Consumer Services | 11 |
| Commercial Services | 3 |
| Technology Services | 3 |
| Electronic Technology | 2 |
Operational
| Director/Board Member | 33 |
| Corporate Officer/Principal | 12 |
| Independent Dir/Board Member | 9 |
| Chief Executive Officer | 5 |
| Undergraduate Degree | 4 |
Most connected contacts
| Insiders | |
|---|---|
| John McHutchison | 14 |
| Paul Carter | 12 |
| Sarah Gordon-Wild | 11 |
| Per Lundin | 8 |
| Martin Andrews | 7 |
| Adam Stoten | 2 |
| Matthew Wood | 1 |
- Stock Market
- Insiders
- Amrit Nagpal
- Company connections
